197 related articles for article (PubMed ID: 38378950)
1. Multivalent cytomegalovirus glycoprotein B nucleoside modified mRNA vaccines did not demonstrate a greater antibody breadth.
Wang HY; Li L; Nelson CS; Barfield R; Valencia S; Chan C; Muramatsu H; Lin PJC; Pardi N; An Z; Weissman D; Permar SR
NPJ Vaccines; 2024 Feb; 9(1):38. PubMed ID: 38378950
[TBL] [Abstract][Full Text] [Related]
2. Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization.
Nelson CS; Jenks JA; Pardi N; Goodwin M; Roark H; Edwards W; McLellan JS; Pollara J; Weissman D; Permar SR
J Virol; 2020 Apr; 94(9):. PubMed ID: 32051265
[TBL] [Abstract][Full Text] [Related]
3. HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions.
Nelson CS; Huffman T; Jenks JA; Cisneros de la Rosa E; Xie G; Vandergrift N; Pass RF; Pollara J; Permar SR
Proc Natl Acad Sci U S A; 2018 Jun; 115(24):6267-6272. PubMed ID: 29712861
[TBL] [Abstract][Full Text] [Related]
4. Intrahost Dynamics of Human Cytomegalovirus Variants Acquired by Seronegative Glycoprotein B Vaccinees.
Nelson CS; Vera Cruz D; Su M; Xie G; Vandergrift N; Pass RF; Forman M; Diener-West M; Koelle K; Arav-Boger R; Permar SR
J Virol; 2019 Mar; 93(5):. PubMed ID: 30518646
[TBL] [Abstract][Full Text] [Related]
5. Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses Than the gB/MF59 Vaccine.
Hu X; Karthigeyan KP; Herbek S; Valencia SM; Jenks JA; Webster H; Miller IG; Connors M; Pollara J; Andy C; Gerber LM; Walter EB; Edwards KM; Bernstein DI; Hou J; Koch M; Panther L; Carfi A; Wu K; Permar SR
J Infect Dis; 2024 Feb; ():. PubMed ID: 38324766
[TBL] [Abstract][Full Text] [Related]
6. Pre-existing immunity to cytomegalovirus in macaques influences human CMV vaccine responses in preclinical models.
Webster H; Valencia S; Kumar A; Chan C; Dennis M; Roark H; Woods A; John S; Carfi A; Permar SR
Vaccine; 2021 Sep; 39(38):5358-5367. PubMed ID: 34393017
[TBL] [Abstract][Full Text] [Related]
7. Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector.
Schleiss MR; Berka U; Watson E; Aistleithner M; Kiefmann B; Mangeat B; Swanson EC; Gillis PA; Hernandez-Alvarado N; Fernández-Alarcón C; Zabeli JC; Pinschewer DD; Lilja AE; Schwendinger M; Guirakhoo F; Monath TP; Orlinger KK
Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27795301
[TBL] [Abstract][Full Text] [Related]
8. Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice.
Chiuppesi F; Nguyen J; Park S; Contreras H; Kha M; Meng Z; Kaltcheva T; Iniguez A; Martinez J; La Rosa C; Wussow F; Diamond DJ
J Virol; 2018 Oct; 92(19):. PubMed ID: 30045984
[TBL] [Abstract][Full Text] [Related]
9. Vaccination with a replication-defective cytomegalovirus vaccine elicits a glycoprotein B-specific monoclonal antibody repertoire distinct from natural infection.
Valencia SM; Rochat E; Harnois MJ; Dennis M; Webster HS; Hora B; Kumar A; Wang HS; Li L; Freed D; Zhang N; An Z; Wang D; Permar SR
NPJ Vaccines; 2023 Oct; 8(1):154. PubMed ID: 37816743
[TBL] [Abstract][Full Text] [Related]
10. Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation.
Baraniak I; Gomes AC; Sodi I; Langstone T; Rothwell E; Atkinson C; Pichon S; Piras-Douce F; Griffiths PD; Reeves MB
EBioMedicine; 2019 Dec; 50():45-54. PubMed ID: 31735553
[TBL] [Abstract][Full Text] [Related]
11. Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies.
Baraniak I; Kropff B; Ambrose L; McIntosh M; McLean GR; Pichon S; Atkinson C; Milne RSB; Mach M; Griffiths PD; Reeves MB
Proc Natl Acad Sci U S A; 2018 Jun; 115(24):6273-6278. PubMed ID: 29686064
[TBL] [Abstract][Full Text] [Related]
12. A temperature-dependent virus-binding assay reveals the presence of neutralizing antibodies in human cytomegalovirus gB vaccine recipients' sera.
Gomes AC; Baraniak IA; McIntosh MR; Sodi I; Langstone T; Siddiqui S; Atkinson C; McLean GR; Griffiths PD; Reeves MB
J Gen Virol; 2023 Jun; 104(6):. PubMed ID: 37310000
[TBL] [Abstract][Full Text] [Related]
13. The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB.
Lilja AE; Mason PW
Vaccine; 2012 Nov; 30(49):6980-90. PubMed ID: 23041121
[TBL] [Abstract][Full Text] [Related]
14. Antibody binding to native cytomegalovirus glycoprotein B predicts efficacy of the gB/MF59 vaccine in humans.
Jenks JA; Nelson CS; Roark HK; Goodwin ML; Pass RF; Bernstein DI; Walter EB; Edwards KM; Wang D; Fu TM; An Z; Chan C; Permar SR
Sci Transl Med; 2020 Nov; 12(568):. PubMed ID: 33148624
[TBL] [Abstract][Full Text] [Related]
15. Comparison of monovalent glycoprotein B with bivalent gB/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: Inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection against pup mortality.
Swanson EC; Gillis P; Hernandez-Alvarado N; Fernández-Alarcón C; Schmit M; Zabeli JC; Wussow F; Diamond DJ; Schleiss MR
Vaccine; 2015 Jul; 33(32):4013-8. PubMed ID: 26079615
[TBL] [Abstract][Full Text] [Related]
16. Novel trimeric human cytomegalovirus glycoprotein B elicits a high-titer neutralizing antibody response.
Cui X; Cao Z; Wang S; Lee RB; Wang X; Murata H; Adler SP; McVoy MA; Snapper CM
Vaccine; 2018 Sep; 36(37):5580-5590. PubMed ID: 30082162
[TBL] [Abstract][Full Text] [Related]
17. DNA vaccine prime followed by boost with live attenuated virus significantly improves antigen-specific T cell responses against human cytomegalovirus.
Gil A; Shen S; Coley S; Gibson L; Diamond DJ; Wang S; Lu S
Hum Vaccin Immunother; 2013 Oct; 9(10):2120-32. PubMed ID: 24051429
[TBL] [Abstract][Full Text] [Related]
18. Human cytomegalovirus (HCMV) infection/re-infection: development of a protective HCMV vaccine.
Gerna G; Lilleri D
New Microbiol; 2019 Jan; 42(1):1-20. PubMed ID: 30671581
[TBL] [Abstract][Full Text] [Related]
19. Molecular analysis of the immune response to human cytomegalovirus glycoprotein B (gB). II. Low gB-specific T and B cell responses are associated with expression of certain HLA-DR alleles.
Curtsinger JM; Liu YN; Radeke R; Bryon MK; Fuad S; Bach FH; Gehrz RC
J Gen Virol; 1994 Feb; 75 ( Pt 2)():301-7. PubMed ID: 8113751
[TBL] [Abstract][Full Text] [Related]
20. Cell Fusion Induced by a Fusion-Active Form of Human Cytomegalovirus Glycoprotein B (gB) Is Inhibited by Antibodies Directed at Antigenic Domain 5 in the Ectodomain of gB.
Reuter N; Kropff B; Schneiderbanger JK; Alt M; Krawczyk A; Sinzger C; Winkler TH; Britt WJ; Mach M; Thomas M
J Virol; 2020 Aug; 94(18):. PubMed ID: 32641474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
